Introduction: The legalization of cannabinoids for medical use has reinforced their emerging role as a treatment of chronic pain in patients with rheumatic diseases [ref:1]. While an immunosuppressive effect of cannabinoids has been postulated, it could not be confirmed in clinical trials,[for full text, please go to the a.m. URL]
Deutscher Rheumatologiekongress 2020, 48. Kongress der Deutschen Gesellschaft für Rheumatologie (DGRh), 34. Jahrestagung der Deutschen Gesellschaft für Orthopädische Rheumatologie (DGORh)